Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00723957 · ClinicalTrials.gov registry record · Phase 2
A Randomized Phase 2 Study of Ixabepilone Plus Carboplatin and Paclitaxel Plus Carboplatin in Advanced Nonsmall-Cell Lung Cancer
A Phase 2 study, sponsored by R-Pharm.
- Completed
- Registry status
- Phase 2
- Development phase
- 260
- Enrollment target
NCT00723957 is a Phase 2 study that has completed, run by R-Pharm. The registered enrollment target is 260 participants.
The verdict
NCT00723957, a Phase 2 study, has completed, sponsored by R-Pharm.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 260 participants
- Enrollment target
Study Summary
The purpose of this study is to determine whether progression-free survival with ixabepilone is superior to that achieved with paclitaxel plus carboplatin in participants with advanced nonsmall-cell lung cancer and beta III (βIII)-tubulin-positive tumors.
Interventions
- DRUG Ixabepilone, 32 mg/m^2
- DRUG Paclitaxel, 200 mg/m^2
- DRUG Carboplatin (area under the concentration curve [AUC] 6)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 260 participants |
| Start Date | 2008-12 |
| Est. Completion | 2011-08 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00723957
The ClinicalTrials.gov registry entry for NCT00723957 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 260 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is R-Pharm, which has 19 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Ixabepilone, 32 mg/m^2 is the first listed.
NCT00723957 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00723957 about?
NCT00723957 is a clinical study titled "A Randomized Phase 2 Study of Ixabepilone Plus Carboplatin and Paclitaxel Plus Carboplatin in Advanced Nonsmall-Cell Lung Cancer". The purpose of this study is to determine whether progression-free survival with ixabepilone is superior to that achieved with paclitaxel plus carboplatin in participants with advanced nonsmall-cell lung cancer and beta III (βIII)-tubulin-positive tumors.
What is the current status of trial NCT00723957?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 260 participants. The study started on 2008-12. Estimated completion is 2011-08.
What interventions are being tested in trial NCT00723957?
The interventions under investigation include: Ixabepilone, 32 mg/m^2 (DRUG), Paclitaxel, 200 mg/m^2 (DRUG), Carboplatin (area under the concentration curve [AUC] 6) (DRUG).
Who is sponsoring clinical trial NCT00723957?
This trial is sponsored by R-Pharm, which has 19 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.